Fraunhofer Institute for Toxicology and Experimental Medicine

Finding a drug against corona

Interview with Prof. Armin Braun and Prof. Mark von Itzstein regarding the enhancement of the German-Australian iCAIR® project to include the coronavirus SARS-CoV-2.

more info

EU project MDOT

Development of an open-innovation test bed to support small and medium-sized manufacturers of medical devices in the conformity assessment of their products.

more info

Bioinformatics and Digital Health

Processing large quantities of data is a major challenge of our era, in the life sciences in particular. The Project Group for Bioinformatics has been set up as an “Attract Group” at Fraunhofer ITEM.

more info

Respiratory infections

Fraunhofer ITEM research teams are facing up to the challenges in infection research. Dr. Sabine Wronski, manager of the Working Group on Infection and Immunology, talks about this in an interview.

more info

Annual Report 2019

What were our topics last year? Our Annual Report 2019 provides insights into our highlights, results, and service portfolio.

more info

Twenty years of Fraunhofer ITEM clinical research

Please save the dates November 12 and 13 for our symposium "Experimental Medicine in Lung Disease".

more info

Fighting bacteria with viruses

Fraunhofer scientists have joined forces with partners in the Phage4Cure project to explore alternatives to antibiotics.

more info

Training course on in-silico toxicology

The next training course on in-silico toxicology will take place from December 8 to 10, 2020. Registration is open.

more info

Replacing animal testing

Fraunhofer ITEM advances the development of new-approach methodologies. Our scientists Dr. Sylvia Escher and Dr. Tanja Hansen discussed the paradigm shift in chemical risk assessment.

more info

INFORMATION regarding SARS-CoV-2 and COVID-19

We have been closely observing the global SARS-CoV-2 pandemic since the beginning of this year and our crisis management team has implemented action plans aimed both at protecting our staff and at guaranteeing continuity in projects and ongoing studies to our partners and clients. Should a delay be unavoidable in a project, we will inform you as soon as possible.

The vision and aim of Fraunhofer ITEM are to ensure people's sustainable health and protect them from health hazards. This is the direction we are following with all our strength in the current situation as well.

If you have any questions regarding ongoing projects, we would kindly ask you to contact your project partner at Fraunhofer ITEM directly.

Stay healthy!

Kind regards, Fraunhofer ITEM

Fraunhofer ITEM: News


Press Release / 7.5.2020


Fraunhofer Research consortium iCAIR® makes use of synergies to develop new medications against SARS-CoV-2.

News / 2.4.2020

Give-a-breath challenge

Munich Re and Fraunhofer have launched a global call for ideas to identify the best 3D-printable designs/blueprints for emergency ventilation equipment.

Events / 10.3.2020

SOT Meeting canceled

Responding to the worldwide situation related to COVID-19, the Society of Toxicology has canceled the SOT Annual Meeting scheduled to take place March 15–19, 2020.


News / 17.4.2020

Annual Report 2019

What were our topics last year? Our Annual Report 2019 provides insights into our highlights, results, and service portfolio.

News / 17.2.2020

Keep up and accelerate innovation in biomedical engineering

Thematic forum at Fraunhofer ITEM: new impetus for biomedical engineering 

News / 2.3.2020

Looking back at“Models of Lung Disease”

Impressions of the 19th Fraunhofer seminar "Models of Lung Disease" held on February 6 and 7, 2020.

Our services and expertise

Pioneers for sustainable health

Research at Fraunhofer ITEM is focused on human health – and this has been so for almost four decades.

The emphasis is on two aspects: firstly, on protecting health from potentially harmful, in particular airborne substances, be they gases, aerosols, particles, fibers, or nanomaterials, and secondly, on investigating and developing diagnostic and therapeutic approaches, both at the preclinical and clinical levels.

A special focus is on airway research.


Chemical Safety and Assessment


Translational Biomedical Engineering


Personalized Tumor Therapy


Bioinformatics and Digital Health

The Project Group for Bioinformatics improves the analysis of data collected in health research by using novel intelligent methods.

Focus of our research

The lung and airways are at the focus of our R&D activities. Furthermore, Fraunhofer ITEM engages in the development and manufacturing of biopharmaceuticals, tumor therapy, and translational biomedical engineering.


Fraunhofer ITEM

Fraunhofer Institute for Toxicology and Experimental Medicine ITEM

Nikolai-Fuchs-Strasse 1
30625 Hannover

Phone +49 511 5350-0



Training course: In-silico toxicology

This training course will introduce the participants to three different in-silico approaches for estimation of human health toxicological endpoints, namely QSAR models, read-across, and the TTC (threshold of toxicological concern) concept. The application of in-silico approaches in ecotoxicology will not be addressed in this course.
Read more


International Symposium "Experimental Medicine in Lung Disease"

Twenty years of clinical research at Fraunhofer ITEM is a great opportunity to discuss current issues in clinical lung research with internationally renowned experts. Please save the Dates November 12 and 13 for our symposium "Experimental Medicine in Lung Disease – 20 years of Fraunhofer ITEM Clinical Research".
Read more


DGP Congress 2020

At the 61st Congress of the German Respiratory Society, taking place in Leipzig (Germany) from June 24 to 27, 2020, Fraunhofer ITEM scientists will make contributions to the scientific program.
Read more


Webinar: “Medical silicone rubber in additive fabrication“

Join our webinar on #AdditiveManufacturing to gain insights into additive fabrication with medical-grade silicone rubber.
Read more

About Fraunhofer ITEM

The Fraunhofer Institute for Toxicology and Experimental Medicine ITEM is one of 74 institutions of the Fraunhofer-Gesellschaft, Europe's leading organization for applied research. Protecting man from health hazards in our industrialized world and contributing to the development of novel therapeutic approaches are the aims Fraunhofer ITEM is pursuing with its contract research. With a focus on airway research, our R&D portfolio includes three thematic areas: drug development, chemical safety, and translational biomedical engineering. In addition, our scientists in Regensburg do research in the field of personalized tumor therapy.

With a staff of 357 at its locations in Hannover, Braunschweig and Regensburg, the institute cooperates with industry, service providers, and public authorities in projects that drive economic development and serve the wider benefit of society.

More information about Fraunhofer ITEM